Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleTheranostics

64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor–Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial

Ebrahim S. Delpassand, David Ranganathan, Nilesh Wagh, Afshin Shafie, Ayman Gaber, Ali Abbasi, Andreas Kjaer, Izabela Tworowska and Rodolfo Núñez
Journal of Nuclear Medicine June 2020, 61 (6) 890-896; DOI: https://doi.org/10.2967/jnumed.119.236091
Ebrahim S. Delpassand
1Excel Diagnostics and Nuclear Oncology Center, Houston, Texas
2RadioMedix, Inc., Houston, Texas; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Ranganathan
2RadioMedix, Inc., Houston, Texas; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nilesh Wagh
2RadioMedix, Inc., Houston, Texas; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Afshin Shafie
1Excel Diagnostics and Nuclear Oncology Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ayman Gaber
1Excel Diagnostics and Nuclear Oncology Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali Abbasi
2RadioMedix, Inc., Houston, Texas; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Kjaer
3Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Izabela Tworowska
2RadioMedix, Inc., Houston, Texas; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodolfo Núñez
1Excel Diagnostics and Nuclear Oncology Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 61 no. 6 890-896
DOI 
https://doi.org/10.2967/jnumed.119.236091
PubMed 
31924723

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication September 9, 2019
  • Accepted for publication January 3, 2020
  • Published online June 4, 2020.

Article Versions

  • previous version (January 10, 2020 - 04:59).
  • previous version (January 31, 2020 - 13:36).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Ebrahim S. Delpassand1,2,
  2. David Ranganathan2,
  3. Nilesh Wagh2,
  4. Afshin Shafie1,
  5. Ayman Gaber1,
  6. Ali Abbasi2,
  7. Andreas Kjaer3,
  8. Izabela Tworowska2 and
  9. Rodolfo Núñez1
  1. 1Excel Diagnostics and Nuclear Oncology Center, Houston, Texas
  2. 2RadioMedix, Inc., Houston, Texas; and
  3. 3Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
  1. For correspondence or reprints contact: Rodolfo Núñez, Excel Diagnostics and Nuclear Oncology Center, 9701 Richmond Ave., Suite 122, Houston, TX 77042. E-mail: rnunez{at}exceldiagnostics.com
View Full Text

Statistics from Altmetric.com

Cited By...

  • 45 Citations
  • 66 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy
    Romain Eychenne, Christelle Bouvry, Mickael Bourgeois, Pascal Loyer, Eric Benoist, Nicolas Lepareur
    Molecules 2020 25 17
  • Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
    Juan Sun, Zhenyuan Huangfu, Jiangtao Yang, Guanglin Wang, Kuan Hu, Mingyuan Gao, Zhiyuan Zhong
    Advanced Drug Delivery Reviews 2022 190
  • How We Do It: A Multidisciplinary Approach to 177Lu DOTATATE Peptide Receptor Radionuclide Therapy
    Brian J. Burkett, Ayca Dundar, Jason R. Young, Annie T. Packard, Geoffrey B. Johnson, Thorvardur R. Halfdanarson, Rachel A. Eiring, Denise N. Gansen, Cynthia M. Patton, A. Tuba Kendi
    Radiology 2021 298 2
  • Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals
    Olga O. Krasnovskaya, Daniil Abramchuck, Alexander Erofeev, Peter Gorelkin, Alexander Kuznetsov, Andrey Shemukhin, Elena K. Beloglazkina
    International Journal of Molecular Sciences 2023 24 11
  • Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors
    Satya Das, Arvind Dasari
    Therapeutic Advances in Medical Oncology 2021 13
  • Choice Is Good at Times: The Emergence of [64Cu]Cu-DOTATATE–Based Somatostatin Receptor Imaging in the Era of [68Ga]Ga-DOTATATE
    Abhishek Jha, Mayank Patel, Jorge A. Carrasquillo, Clara C. Chen, Corina Millo, Roberto Maass-Moreno, Alexander Ling, Frank I. Lin, Ronald M. Lechan, Thomas A. Hope, David Taïeb, Ali Cahid Civelek, Karel Pacak
    Journal of Nuclear Medicine 2022 63 9
  • Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors
    Janie Y. Zhang, Pamela L. Kunz
    JCO Oncology Practice 2022 18 4
  • Updates to the Appropriate-Use Criteria for Somatostatin Receptor PET
    Thomas A. Hope
    Journal of Nuclear Medicine 2020 61 12
  • Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens
    Elmira Yazdani, Parham Geramifar, Najme Karamzade-Ziarati, Mahdi Sadeghi, Payam Amini, Arman Rahmim
    Diagnostics 2024 14 2
  • Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
    Anna Yordanova, Hans-Jürgen Biersack, Hojjat Ahmadzadehfar
    Journal of Clinical Medicine 2020 9 11

Article usage

Article usage: January 2020 to April 2025

AbstractFullPdf
Jan 202011860171
Feb 2020505043
Mar 2020174023
Apr 2020147019
May 2020127013
Jun 20208591889
Jul 20202302139
Aug 20201932864
Sep 2020331103147
Oct 20202226478
Nov 20201604283
Dec 20201435977
Jan 20211068364
Feb 2021102136111
Mar 202176126103
Apr 2021669468
May 20215110375
Jun 2021689673
Jul 20215312045
Aug 2021448355
Sep 2021459063
Oct 20214211371
Nov 20214212272
Dec 20212410444
Jan 20224814166
Feb 20223113235
Mar 20222813033
Apr 20224018463
May 20223715453
Jun 20222412848
Jul 20222812926
Aug 20222116455
Sep 20222513744
Oct 20222112329
Nov 20221816431
Dec 20221712029
Jan 20231513633
Feb 20232113535
Mar 20232013539
Apr 20231511038
May 2023913248
Jun 20231113947
Jul 20231012432
Aug 20231212843
Sep 20231913648
Oct 20231514648
Nov 20231919544
Dec 20231019041
Jan 20243422352
Feb 20242119443
Mar 20241921945
Apr 20241819249
May 20241119736
Jun 20241018253
Jul 20241417443
Aug 20241020253
Sep 2024924866
Oct 20241727069
Nov 202419318115
Dec 20241029473
Jan 2025925580
Feb 20252236560
Mar 20251429254
Apr 20251439473
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (6)
Journal of Nuclear Medicine
Vol. 61, Issue 6
June 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor–Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor–Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial
Ebrahim S. Delpassand, David Ranganathan, Nilesh Wagh, Afshin Shafie, Ayman Gaber, Ali Abbasi, Andreas Kjaer, Izabela Tworowska, Rodolfo Núñez
Journal of Nuclear Medicine Jun 2020, 61 (6) 890-896; DOI: 10.2967/jnumed.119.236091

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor–Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial
Ebrahim S. Delpassand, David Ranganathan, Nilesh Wagh, Afshin Shafie, Ayman Gaber, Ali Abbasi, Andreas Kjaer, Izabela Tworowska, Rodolfo Núñez
Journal of Nuclear Medicine Jun 2020, 61 (6) 890-896; DOI: 10.2967/jnumed.119.236091
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Choice Is Good at Times: The Emergence of [64Cu]Cu-DOTATATE-Based Somatostatin Receptor Imaging in the Era of [68Ga]Ga-DOTATATE
  • Updates to the Appropriate-Use Criteria for Somatostatin Receptor PET
  • Google Scholar

More in this TOC Section

Theranostics

  • Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
  • Determination of the Intralesional Distribution of Theranostic 124I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
Show more Theranostics

Clinical

  • TauIQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans
  • Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker
  • Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
Show more Clinical

Similar Articles

Keywords

  • 64Cu-DOTATATE
  • clinical phase III trial
  • prospective study
  • neuroendocrine tumors
  • PET/CT in oncology
SNMMI

© 2025 SNMMI

Powered by HighWire